Opal Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$263K Buy
590
+29
+5% +$13.5K 0.06% 167
2025
Q4
$254K Buy
+561
New +$242K 0.07% 176
2025
Q3
Sell
-164
Closed -$73K 544
2025
Q2
$73K Sell
164
-5
-3% -$2.3K 0.02% 313
2025
Q1
$81.9K Buy
+169
New +$78.8K 0.03% 295
2024
Q3
Sell
-124
Closed -$58.1K 1149
2024
Q2
$58.1K Sell
124
-10
-7% -$4.34K 0.02% 339
2024
Q1
$56K Buy
+134
New +$56.6K 0.02% 207

Other funds holding VRTX

Opal Wealth Advisors's VRTX Position: Q1 2026 in Review

Opal Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 5.2% in Q1 2026, buying an estimated $13.5K and bringing the position to 590 shares worth $263K. The position accounts for 0.06% of the portfolio, ranked #167.

Opal Wealth Advisors first reported a position in VRTX in Q1 2024 and has held it in 6 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Opal Wealth Advisors held 590 shares of Vertex Pharmaceuticals worth $263K as of Q1 2026.
  • Opal Wealth Advisors bought 29 Vertex Pharmaceuticals shares in Q1 2026, an estimated $13.5K.
  • Vertex Pharmaceuticals made up 0.06% of Opal Wealth Advisors's portfolio in Q1 2026, its #167 holding.
  • Opal Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Opal Wealth Advisors's 13F filing for Q1 2026, filed 14 Apr 2026.